Mattia Falchetto Osti

Prof. Mattia Falchetto Osti

University of "La Sapienza", Roma, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2011 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
ECEnrico Clarke
Enrico Clarke
GLGaetano Lanzetta
Gaetano Lanzetta
Mattia Falchetto OstiMattia Falchetto Osti
Mattia Falchetto Osti
GTGuido Trasimeni
Guido Trasimeni
RERiccardo Maurizi Enrici
Riccardo Maurizi Enrici
To investigate the factors affecting survival and toxicity in patients treated with stereotactic radiosurgery (SRS), with special attention to volumes of brain receiving a specific dose (V10 - V16 Gy) as predictors for brain radionecrosis. Two hundred six consecutive patients with 310 cerebral metastases less than 3.5 cm were treated with SRS as primary treatment and followed prospectively at University of Rome La Sapienza Sant'Andrea Hospital. Overall survival, brain control, and local control were estimated using the Kaplan-Meier method calculated from the time of SRS. Univariate and multivariate analysis using a Cox proportional hazards regression model were performed to determine the predictive value of prognostic factors for treatment outcome and SRS-related complications. Median overall survival and brain control were 14.1 months and 10 months, respectively. The 1-year and 2-year survival rates were 58% and 24%, and respective brain control were 43% and 22%. Sixteen patients recurred locally after SRS, with 1-year and 2-year local control rates of 92% and 84%, respectively. On multivariate analysis, stable extracranial disease and KPS >70 were associated with the most significant survival benefit. Neurological complications were recorded in 27 (13%) patients. Severe neurological complications (RTOG Grade 3 and 4) occurred in 5.8% of patients. Brain radionecrosis occurred in 24% of treated lesions, being symptomatic in 10% and asymptomatic in 14%. On multivariate analysis, V10 through V16 Gy were independent risk factors for radionecrosis, with V10 Gy and V12 Gy being the most predictive (p = 0.0001). For V10 Gy >12.6 cm3 and V12 Gy >10.9 cm3 the risk of radionecrosis was 47%. SRS alone represents a feasible option as initial treatment for patients with brain metastases, however a significant subset of patients may develop neurological complications. Lesions with V12 Gy >8.5 cm3 carries a risk of radionecrosis >10% and should be considered for hypofractionated stereotactic radiotherapy especially when located in/near eloquent areas.

1 July 2016 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
CSClaudia Scaringi
Claudia Scaringi
SPSergio Paolini
Sergio Paolini
GLGaetano Lanzetta
Gaetano Lanzetta
ARAndrea Romano
Andrea Romano
VEVincenzo Esposito
Vincenzo Esposito


5 February 2008 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
VSV. De Sanctis
V. De Sanctis
RMR. Muni
R. Muni
FFF. Filippone
F. Filippone
ABA. Bozzao
A. Bozzao
RER. Maurizi Enrici
R. Maurizi Enrici

1 December 2003 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
FVFederico Venuta
Federico Venuta
ERErino A Rendina
Erino A Rendina
FLFlavia Longo
Flavia Longo
TGTiziano De Giacomo
Tiziano De Giacomo
MAMarco Anile
Marco Anile
GCGiorgio F Coloni
Giorgio F Coloni

1 February 2014 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
RDRolando Maria D'Angelillo
Rolando Maria D'Angelillo
CSClaudia Scaringi
Claudia Scaringi
LTLuca E. Trodella
Luca E. Trodella
ECEnrico Clarke
Enrico Clarke
LTLucio Trodella
Lucio Trodella